From 23b497804bad08318b37c2286a8181378099609e Mon Sep 17 00:00:00 2001
From: Vandon T Duong Case 1: $ARAV
- Under development + Replimune is a biotechnology startup developing oncolytic viruses as immunotherapies. These engineered viruses, derived from herpes simplex virus type 1, are designed to activate local and systemic immune response against cancers. Combinations with checkpoint blockade have demonstrated potent tumor response. The company is managed by those who led efforts in developing and commercializing talimogene laherparepvec (T-Vec), the first oncolytic virus approved by the FDA.
ZqY3~HD)q1n4$CrqkuSfX_
z&2W2RdMN>7 <~O3`n8$O(FNs^3gUjzyL=aAGbQN$y28|K}cX*7yZ$
zmvMYzay*TouWvVE$HR0 PQWeO}>8laHQAbQ^HyccY@8Gv2LqW%}?vq9MS7tjEm7)O80=Ss9DcPLxWA^_qJ
zn7w3qWUP*T*G0ydd%>iwVd_bD;Hd_Wy5oTtzXJs$D#lX#BJ1XrD}2hWjs%NPPf!H?
zt}iVF%$xf?8>b1(^HC3(f?ZPV`A*n|EJ-@V~8o
&sGmlnhO1Lc)(*Y_1*m*K356r|ffcAf3256-
zx`X$>Ey@K8Y;A+al0t7#?k$w}`vUmiOe1n_iZteC=96R$hq{^eZuxREa@